ACCESS Newswire

RAUDER

Share
2nd Latin American Nicotine and Risk Reduction Forum in Panama

Global Experts Highlighted the Importance of Reduced-Risk Alternatives in the Comprehensive Fight Against Smoking

PANAMA CITY, PANAMA / ACCESSWIRE / February 6, 2024 / Razón Autonomía Derecho A.C, RAUDER, a non-profit civil association that advocates for human rights, personal autonomy, and the free development of personality, organized the "2nd Latin American Nicotine and Risk Reduction Forum: Science, Regulation, and Activism" that took place today in Panama City. The objective was to analyze and discuss the crucial role of reduced-risk alternatives in the fight against tobacco.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
President of RAUDER and directors of organizations of vaping

The forum brought together legislators, experts, doctors, scientists, and activists from across the globe. They emphasized the importance of developing public policies that aim towards harm reduction and respect for human rights, and called for a humane and effective approach, that respects consumers' rights and provides safe, science-based regulated options.

Conversations were around studies and relevant practices from various countries on how alternatives, such as vapor products, can significantly contribute to harm reduction in smoking. Participants emphasized that their prohibition in countries such as Mexico, Brazil and Panama has led to an increase in illegal trade and limits smokers' options to access safer alternatives.

"It is essential to recognize and regulate vapor products as reduced-risk alternatives. Prohibition not only prevents smokers from legal options but drives the black market, and gives easier access to minors besides all the other negative consequences that it implies," explained Rafael Lara Liy, RAUDER's director.

Lara also emphasized the importance of science-based information in enabling consumers to make informed decisions; he stressed the need for all voices to be considered in developing public policies. "Prohibition does not work nor does it solve the problem; the whole of society has the right to participate in shaping public policy. We want to contribute a perspective that also considers consumers' rights and information based on scientific evidence regarding reduced-risk alternatives," he said.

Doctor Marina Hoyo, a forum's panelist, said: "As health professionals, we have a responsibility to stay up to date, analyze, understand, and question the evidence. But we also need to approach our patient care from a position of empathy towards people seeking to improve their health. That's why we must consider alternatives that reduce risks. This is the foundation of a therapeutic bond that aims to truly help the individual and not stigmatize them, but rather try to alleviate their condition."

Contact Information:

Joel Hernandez
PR DIRECTOR
joel@nimbus.mx
+524421244955

Related Files
240206 Press Release RAUDER Forum Panama.pdf

SOURCE: RAUDER

To view this piece of content from stats.newswire.com, please give your consent at the top of this page.

View the original press release on newswire.com.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release

Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres

General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release

DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG

OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release

OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper

Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release

VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc

GA-ASI Completes Full-Scale Fatigue Test on MQ-9B17.11.2025 03:10:00 CET | Press release

MQ-9B's Third Lifetime Test Completes the FSF Testing Process With a Total of 120,000 Hours DUBAI, UAE / ACCESS Newswire / November 16, 2025 / On October 31, 2025, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed its "third lifetime" of full-scale fatigue (FSF) testing for the MQ-9B Remotely Piloted Aircraft (RPA). Completion of FSF testing for the third and final lifetime includes a total of 120,000 operating hours (40,000+ flight hours per aircraft life) for the RPA and is a key milestone in validating the design of the airframe. The testing verifies the airframe structural integrity in support of certification to the NATO STANAG 4671 standard. The aim of the testing is to identify any potential structural deficiencies ahead of fleet usage and assist in developing inspection and maintenance schedules for the airframe. Test results will be used as documentation for certification and will form the basis for in-service inspections of structural components. "The completion o

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye